| Use of mouse mammary tumour virus (MMTV)/neu transgenic mice to identify genes collaborating with the c-erbB-2 oncogene in mammary tumour development. | None |
| The ErbB-2/HER2 oncogenic receptor of adenocarcinomas: from orphanhood to multiple stromal ligands. | None |
| The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin. | None |
| Correlation of p34cdc2 cyclin-dependent kinase overexpression, CD44s downregulation, and HER-2/neu oncogene amplification with recurrence in prostatic adenocarcinomas. | None |
| Prognostic significance of c-erbB-2 oncoprotein expression in intestinal-type adenocarcinoma of the sinonasal tract. | None |
| Expression of HER-2/neu oncogene in normal, hyperplastic, and malignant endometrium. | None |
| Absence of autophosphorylation site Y882 in the p185neu oncogene product correlates with a reduction of transforming potential. | None |
| Expression of the c-erbB-2-encoded oncoprotein p185 (HER-2/neu) in pregnancy as a model for oncogene-induced carcinogenesis. | None |
| Isolation of the intact molecule and ectodomain of C-erbB-2 oncoprotein from SK-BR-3 cells and development of immunoassays on microplate. | None |
| Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. | None |
| Neu differentiation factor (NDF), a dominant oncogene, causes apoptosis in vitro and in vivo. | None |
| The her-2/neu oncogene stimulates the transcription of N-acetylglucosaminyltransferase V and expression of its cell surface oligosaccharide products. | None |
| Amplification and expression of the c-erbB-2 oncogene in Mullerian-derived genital-tract tumors. | None |